clinical trial · NCT02029443
ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia
Acerta Pharma BV·phase2·active not recruiting·n = 306
Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaRichter's SyndromeProlymphocytic LeukemiaAcalabrutinib
brief summary
This study is evaluating the safety and efficacy of a new BTK inhibitor, acalabrutinib, for the treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
started
Jan 30, 2014
primary completion
Jul 15, 2021
completion
Jun 9, 2027
last updated
May 5, 2026
official title
A Phase 1/2, Multicenter, Open-label, and Dose-escalation Study of ACP-196 in Subjects With Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol